



August 28, 2020

To,

Manager (CDR)  
Bombay Stock Exchange Limited (BSE)  
P.J. Towers, Dalal Street,  
Mumbai-400001.

**Ref: DR LALCHANDANI LABS LIMITED (Scrip Code: 541299)**

Subject: Revised Financial Results for the half year and year ended 31.03.2020.

Dear Sir/ Madam,

We hereby submitting the Revised Audited Financial Results for the half year and year ended March 31, 2020.

1. Audited Financial Results for the half year and year ended as on March 31, 2020.
2. Audited Statement of Assets and Liabilities for the half year and year ended as on March 31, 2020.
3. Cash Flow Statement for the half year and year ended as on March 31, 2020.
4. Audit report for the half year and year ended as on March 31, 2020.

Please take the same on your record.

Thanking You,

Yours Faithfully,

**For DR LALCHANDANI LABS LIMITED**



**Arjan Lalchandani**  
Managing Director  
DIN: 07014579

Encl: As Above



**DR LALCHANDANI LABS LIMITED**

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: info@lalchandaniplab.com

Phone: 8010689689/ 8010998844

**AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2020***Amount Rs. in Lacs*

Sr. No.	Particulars	Half Year Ended			For the Year Ended	Previous Year Ended
		31.03.2020	30.09.2019	31.03.2019	31.03.2020	31.03.2019
		Audited	Un-audited	Audited	Audited	Audited
I	Revenue from Operations	306.96	303.43	264.14	610.39	526.10
II	Other Income		-	0.57	-	0.57
III	Total Revenue (I+II)	<b>306.96</b>	<b>303.43</b>	<b>264.71</b>	<b>610.39</b>	<b>526.67</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	63.42	51.20	21.60	114.62	60.57
	(b) Purchases of stock in trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work in progress and stock in trade	-	-	-	-	-
	(d) Employee benefits expense	41.94	44.27	43.05	86.21	94.59
	(e) Finance Cost	9.29	9.21	4.59	18.50	13.63
	(f) Depreciation and amortisation expense	21.76	20.54	19.67	42.30	34.89
	(g) Other Expenses	147.58	135.10	130.27	282.68	251.09
	<b>Total Expenses</b>	<b>283.99</b>	<b>260.32</b>	<b>219.18</b>	<b>544.30</b>	<b>454.77</b>
V	Profit before exceptional and extraordinary items and tax (III - IV)	22.97	43.11	45.53	66.08	71.90
VI	Exceptional Items					
VII	Profit extraordinary items and tax (V - VI)	22.97	43.11	45.53	66.08	71.90
VIII	Extraordinary Items					
IX	Profit before tax (VIII - IX)	22.97	43.11	45.53	66.08	71.90
X	Tax Expenses :					
	(1) Current Tax	15.81	-	8.92	15.81	15.77
	(2) Deferred Tax	2.84	-	2.78	2.84	2.78
XI	Profit / (Loss) from Period from continuing operations (IX-X)	4.32	43.11	33.84	47.43	53.35
XII	Profit (Loss) from discontinuing Operations					
XIII	Tax Expense of Discontinuing operations					
XIV	Profit / (Loss) from Discontinuing operations (After Tax XII- XIII)				-	-
XV	Profit (Loss) for the period (XI +XIV)	4.32	43.11	33.84	47.43	53.35
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)					
	(a) Basic (Rs.)	<b>0.10</b>	<b>0.99</b>	<b>0.78</b>	<b>1.09</b>	<b>1.23</b>

(b) Diluted (Rs.)	0.10	0.99	0.78	1.09	1.23
-------------------	------	------	------	------	------

**Notes:**

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on July 28, 2020.
2. There were no investor complaints received / pending as at 31st March, 2020
3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.
4. The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary.

**For Dr Lalchandani Labs Limited,**



**(Dr. Arjan Lalchandani)**

**Managing Director (DIN: 07014579)**

**New Delhi**

**28-Jul-20**

**DR LALCHANDANI LABS LIMITED**

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandaniplab.com/>, Email id: [info@lalchandaniplab.com](mailto:info@lalchandaniplab.com)

Phone: 8010689689/ 8010998844

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES THE HALF YEAR ENDED AND THE YEAR ENDED 31ST MARCH, 2020***Amount in Rs. Lacs*

Sr. No.	Particulars	For the Year Ended	
		31.03.2020	31.03.2019
<b>1</b>	<b>Shareholders' Funds</b>		
	(a) Share Capital	433.31	433.31
	(b) Reserves and Surplus	420.76	373.33
	(c) Money received against share warrants		
	<b>Sub-total-Shareholders' Funds</b>	<b>854.07</b>	<b>806.64</b>
<b>2</b>	<b>Share application money pending allotment</b>		
<b>3</b>	<b>Non Current Liabilities</b>		
	(a) Long Term Borrowings	170.85	85.46
	(b) Deferred Tax Liability	8.01	5.17
	(c) Other Long Term Liabilities		
	(d) Long Term Provisions		
	<b>Sub-total-Non Current Liabilities</b>	<b>178.86</b>	<b>90.62</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	5.01	5.00
	(b) Trade Payables		
	(i) Total Outstanding dues of micro enterprises and small enterprises	10.06	8.68
	(ii) Total Outstanding dues of creditors other than micro enterprises and small enterprises	102.30	55.92
	(c) Other Current Liabilities	27.31	28.10
	(d) Short Term Provisions	15.81	15.77
	<b>Sub-total-Current Liabilities</b>	<b>160.49</b>	<b>113.47</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>1,193.42</b>	<b>1,010.74</b>
<b>II</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Fixed Assets		
	(i) Tangible assets	331.63	312.12
	(ii) Intangible assets	15.49	15.91
	(b) Non Current Investments	24.10	24.10
	(c) Long Term Loans & Advances	31.75	31.75
	(d) Other Non Current Assets	34.30	45.74
	<b>Sub-total-Non Current Assets</b>	<b>437.26</b>	<b>429.61</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Current Investments	-	-
	(b) Inventories	49.70	39.21
	(c) Trade Receivables	332.75	180.70
	(d) Cash & cash equivalents	225.28	202.40

(e) Short Term Loans & Advances	106.17	105.24
(f) Other Current Assets	42.26	53.57
<b>Sub-total-Current Assets</b>	<b>756.16</b>	<b>581.13</b>
<b>TOTAL ASSETS</b>	<b>1,193.42</b>	<b>1,010.74</b>

For Dr Lalchandani Labs Limited



**Dr. Arjan Lalchandani**  
**(Managing Director DIN: 07014579)**

**New Delhi**  
**28-Jul-20**

**DR LALCHANDANI LABS LIMITED**

(CIN: L85320DL2017PLC321605)

Regd. Office: M-20 Basement, Greater Kailash-1, New Delhi -110048.

Website: <http://lalchandanipathlab.com/>, Email id: info@lalchandanipathlab.com

Phone: 8010689689/ 8010998844

**Cash Flow Statement for the Year Ended 31.03.2020**

	<b><u>Particulars</u></b>	<b><u>Amount</u></b> (in Rs. Lacs)
<b>A</b>	<b><u>Cash Flow From Operating Activities</u></b>	
	Net Profit/(Loss) Before Tax	66.08
	Adjustment For:	
	Depreciation	42.30
	Interest Expense	9.15
	<u>Operating Profit Before Working Capital Changes</u>	<u>51.45</u>
		117.54
	<u>Changes in Working Capital</u>	
	Change in Sundry Debtors	(152.05)
	Change in Other Current Assets & Non Current Assets	22.75
	Change in Trade Payables	47.76
	Changes in Inventories	(10.50)
	Change in Other Current Liabilities	(0.79)
	Direct Taxes Paid	(15.77)
	<u>Net Cash Flows From Operating Activities(A)</u>	<u>(108.59)</u>
		8.95
<b>B</b>	<b><u>Cash Flow From Investing Activities</u></b>	
	Purchase of Fixed Assets	(61.39)
	Loans and Advances given	(0.93)
	<u>Net Cash Flow From Investing Activities (B)</u>	<u>(62.32)</u>
<b>C</b>	<b><u>Cash Flow From Financing Activities</u></b>	
	Long Term Borrowings taken	85.40
	Interest Paid	(9.15)
	<u>Net Cash Flow From Financing Activities ( C)</u>	<u>76.25</u>
	<u>Net Change in Cash (A+B+C)</u>	<u>22.88</u>
	<b>Cash and Cash Equivalents at the Beginning of Year</b>	<u>202.40</u>
	<b>Cash and Cash Equivalents at the End of Year</b>	<u>225.28</u>

For Dr Lalchandani Labs Limited



**Dr. Arjan Lalchandani**  
**(Managing Director DIN: 07014579)**

**New Delhi**  
**28-Jul-20**



# Jain Agarwal & Company

Chartered Accountants

TO

**THE BOARD OF DIRECTORS OF  
DR LALCHANDANI LABS LIMITED**

We have audited the yearly Financial Results of Dr Lalchandani Labs Limited for the year ended 31<sup>st</sup> March, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These Financial Results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

Covid-19 has put significant accounting and auditing challenges due to the Government's restrictions imposed during the lockdown for safety concerns. We have performed alternate audit procedures based on documents and information made available and relied upon by us.

Covid Impact - In view of the highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent of the circumstances, as they evolve.

Our conclusion is not modified in respect of this matter.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the year ended 31<sup>st</sup> March, 2020.

**For Jain Agarwal and Company**

Chartered Accountants

FRN.: 024866N

New Delhi

**CA Karan Jain**

(Partner)

M.No.: 521992

UDIN: 20521992AAAAAS8083

Place: New Delhi

Date: 28<sup>th</sup> July, 2020